Precision. Passion.

ProCure's mission is to improve the lives of patients with cancer by increasing access to proton therapy.

Access to innovative proton therapy cancer treatment continues for Oklahomans

Experienced investors acquire Oklahoma City proton therapy center

OKLAHOMA CITY (January 23, 2019) - An investor group with strong local ties announced today the closing
of its acquisition of the Oklahoma City proton therapy center from ProCure. Allied Health Management (AHM) led the sale transaction and will provide ongoing management services at the center. Arvest Bank provided additional financial support for the transaction. The partnership allows the center to invest in equipment upgrades and secures a strong, long-term financial foundation. The center, which opened in 2009, will now operate under the name The Oklahoma Proton Center.

“This facility has been an important resource for the healthcare community in Oklahoma, and we are honored to provide the financial support and leadership to ensure the center continues to offer proton therapy to cancer patients in our region,” said The Oklahoma Proton Center President Tom Welch, a partner in AHM. “Our 45 employees, many of whom have been with the center since it opened, are experts in the industry and are committed to providing excellent clinical care and patient experiences. They have treated more than 2,000 patients over the past 10 years and are truly the heart of our operations. We look forward to working with them to continue to serve cancer patients across the state and region.”

AHM brings an experienced management team with a collective 22 years of leadership in the proton therapy industry. The additional management team members include Chris Brown, chief financial officer, and David Raubach, chief development officer, an Oklahoma native and former employee of the Oklahoma City proton therapy center.

“It is a privilege for me to return to the place where my career started in the proton therapy industry nine years ago and rejoin a great team at a facility that is a landmark in Oklahoma,” Raubach said. “I am extremely excited about the future of the center and the opportunities that lie ahead. Oklahomans are very fortunate to have access to proton therapy within the state, and we are proud to be a part of transforming patients’ lives. We look forward to collaborating with other healthcare providers who are playing a critical role in cancer patients’ treatment journeys.”

The Oklahoma Proton Center will retain its nationally-recognized physicians while also welcoming two leaders in the oncology field. Dr. Andrew Chang and Dr. Les Yonemoto will continue their longstanding relationship with the center, having treated patients there since 2012. Chang and Yonemoto bring a combined 40 years of proton therapy experience. Joining them at the facility are Dr. John Chang and Dr. Mark Storey, who will serve as joint medical directors for The Oklahoma Proton Center.

Dr. John Chang is a recognized leader in the field of proton therapy, having recently served as the director of clinical research and education at Northwestern Medicine’s Proton Center in Chicago, Illinois and subsequently at Vanderbilt University Medical Center in Nashville, Tennessee. He is the principal investigator for numerous pediatric and adult proton therapy clinical trials, has been extensively published and serves as peer-review editor for two prominent industry publications.

“This center and its dedicated staff and physicians have provided outstanding clinical care for cancer patients since its inception,” Dr. John Chang said. “We are excited for the opportunity to work with this dedicated team and provide excellent patient care. We will focus on combining quality care with technological innovations and groundbreaking research collaborations locally, nationally and globally. Our vision is to make Oklahoma a premier region for cancer treatment.”

Dr. Storey completed his training at MD Anderson in Houston, Texas and has practiced the past 17 years in Little Rock, Arkansas. Additionally, he has served as president for one of the largest private radiation oncology groups in the region for the last 11 years. Dr. Storey brings a wealth of clinical and business leadership experience, including serving on the board of one of the largest independent nonprofit cancer centers in the country.

“Proton therapy is the future of radiation oncology,” Dr. Storey said. “While it was a difficult decision to leave home, I am thrilled to be joining an experienced management team at a state-of-the-art facility and continue innovating in the field of radiation oncology.”

About proton therapy:
More than 150,000 patients have been treated with proton therapy worldwide, and the number is increasing with access to 29 proton therapy centers in the U.S. Traditional conventional radiation therapy, even with the most advanced delivery of intensity modulated (IMRT) and stereotactic guidance (SBRT), uses high powered x-rays yielding radiation exposure throughout its path, which spans from skin surface facing the treatment machine through the internal tissues to skin surface on the other side. Proton therapy provides the same curative benefits of conventional radiation therapy, but their nature as high-speed particles allows protons to be directed and stopped at a target region without any further radiation exposure beyond the intended area. Thus, high doses of radiation can be targeted at a tumor with minimal to no collateral radiation exposure to surrounding healthy tissue and organs. Patients can experience fewer side effects and a reduced risk of secondary cancer and other long-term health problems. Proton therapy is routinely used to treat all solid tumors including prostate, breast, brain, spinal, head and neck, lung, gastrointestinal cancers, sarcomas and pediatric tumors.

About Allied Health Management:
Allied Health Management (AHM) was founded in 2018 by partners David Raubach, Tom Welch and Chris Brown. Raubach, Welch and Brown most recently worked at Provision Healthcare in various senior leadership positions. They have a collective 22 years of experience in the proton therapy industry and have participated in the development, start-up and operations of seven proton therapy centers in the U.S.

Media Contact: Laura Rudicel, Saxum
Office: (817) 897-1170
LRudicel@saxum.com

Copyright 2014 © ProCure. All Rights Reserved. The Web site for ProCure Treatment Centers, Inc., including its contents and programs, is provided for informational and educational purposes only. It is not intended as medical advice, nor is it intended to create any physician-patient or clinical relationship. This information is not a substitute for a consultation with your healthcare provider. The views and opinions expressed on this Web site do not necessarily reflect those of ProCure Treatment Centers, Inc. By using this Web site, you accept the Terms of Use. Please read our Privacy Statement.